Lapatinib (Tykerb®, GlaxoSmithKline, London-Brentford, UK) is such an inhibitor targeting the receptor tyrosine kinase and EGFR-member ErbB2 to treat breast cancer (BC). This evidence concerns the gene NTRK1 and breast cancer.